Breast Cancer

Perioperative pembrolizumab plus chemotherapy improved survival vs preoperative chemotherapy in high-risk, early-stage, triple-negative breast cancer.

Ribociclib plus endocrine therapy bested combination chemotherapy in terms of progression-free survival in HR-positive, HER2-negative advanced breast cancer.

Most women who attempted to conceive following treatment for stage I to III breast cancer were able to become pregnant at least once.

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ASCO Annual Meeting.

Guardant360 CDx received In Vitro Diagnostic Regulation certification for tumor mutation profiling in solid tumors and for companion diagnostic indications in NSCLC and breast cancer.

Inavolisib/palbociclib/fulvestrant was granted FDA granted breakthrough therapy designation for PIK3CA-mutated, HR-positive/HER2-negative breast cancer.

Timothy Yap, MBBS, PhD, FRCP, discusses encouraging data seen with the first-in-class PARP1 selective inhibitor saruparib in solid tumors and how the agent is being further investigated.

Medical experts examine the current standards of care and successive lines of treatment for HER2-positive metastatic breast cancer, while also addressing the challenges encountered in managing this complex disease.

Tiffany A. Traina, MD; Vijayakrishna Gadi, MD, PhD, and Heather McArthur, MD, underscore the importance of testing all early-stage and breast cancer patients for HER2 positivity to inform and guide optimal therapeutic decision-making.

Dose reductions of ribociclib plus an NSAI did not decrease the regimen’s efficacy in patients with HR-positive, HER2-negative early breast cancer.

PF-07220060 plus endocrine therapy was tolerable and generated robust response rates in HR-positive, HER2-negative metastatic breast cancer.

Adding denosumab to neoadjuvant nab-paclitaxel did not improve 5-year invasive disease-free survival rates in patients with early-stage breast cancer.

Samilia Obeng-Gyasi, MD, MPH, discusses a retrospective study on neighborhood opportunity and all-cause mortality in patients with breast cancer.

Capivasertib plus fulvestrant improved time to second progression in patients with pretreated HR-positive, HER2-negative advanced breast cancer.

Datopotamab deruxtecan was associated with lower rates of high-grade TRAEs vs chemotherapy in the phase 3 TROPION-Breast01 trial.

Vepdegestrant plus palbociclib maintained clinical efficacy and safety in patients with pretreated, advanced ER-positive, HER2-negative breast cancer.

Carol M. Mangione, MD, discusses the ramifications of the US Preventative Task Force’s April decision to update the breast cancer screening guidelines.

Atezolizumab plus chemotherapy did not improve OS vs chemotherapy alone in select patients with early relapsing triple-negative breast cancer.

Olaparib, durvalumab, and fulvestrant produced a 66.7% 24-week PFS rate in patients with endocrine-resistant, ER-positive, HER2-negative breast cancer.

First-line atezolizumab plus sacituzumab govitecan led to responses in PD-L1–positive locally advanced or metastatic triple-negative breast cancer.

Samilia Obeng-Gyasi, MD, MPH, highlights a study on the association between neighborhood opportunity with all-cause mortality in patients with breast cancer.

Samilia Obeng-Gyasi, MD, MPH, expands on the impact of social determinants of health on breast cancer care.

Timothy Yap, MBBS, PhD, FRCP, discusses data for saruparib in harboring BRCA1/2, PALB2, or RAD51C/D mutations.

Parul N Barry, MD, discusses the integration of partial breast irradiation therapy into the treatment of patients with breast cancer.